Recent research [ 37 ] found no significant survival benefit from surgery across most subgroups, but noted a slight trend toward better progression-free outcomes in triple-positive patients.
← all excerpts
Real-World Efficacy and Adherence to Palbociclib in HR-Positive, HER2-Negative Advanced Breast Cancer: Insights from a Romanian Cohort.
1
—
—